Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions

GERHARD BAUER, a MAGDI ELSALLAB, b MOHAMED ABOU-EL-ENEIN b

Key Words. Stem cells • Mesenchymal stromal cells • Stem cell tourism • Stem cell clinics • Unproven interventions • Regulations • Clinical trials • Ethics • Adverse events • Risks • Hype

ABSTRACT

The promise of stem cell (SC) therapies to restore functions of damaged tissues and organs brings enormous hope to patients, their families, loved ones, and caregivers. However, limits may exist for which indications SC therapies might be useful, efficacious, and safe. Applications of innovative therapies within regulatory boundaries and within the framework of controlled clinical trials are the norm in the scientific and medical community; such a system minimizes patient risk by setting a clear and acceptable safety and efficacy profile for new therapeutics before marketing authorization. This careful clinical validation approach often takes time, which patients suffering from terminal or debilitating diseases do not have. Not validated, unproven stem cell interventions (SCI) that promise a working treatment or cure for severe diseases have therefore found their way into the patient community, and providers of such treatments often take advantage of the public’s willingness to pay large amounts of money for the misguided hope of a reliable recovery from their illnesses. We conducted a review of scientific publications, clinical case reports, and mass media publications to assess the reported cases and safety incidents associated with unproven SCI. The review also analyzes the main factors that were identified as contributing to the emergence and global rise of the “stem cell tourism” phenomenon.

SIGNIFICANCE STATEMENT

Recent reports have been documenting the increase in clinics advertising unproven stem cell (SC) interventions which promise to treat and even cure certain diseases, despite the lack of scientific evidence for their safety and efficacy. This review presents a detailed, up-to-date assessment of the available, reported cases receiving such interventions. This assessment is highly significant, as it joins other efforts in shedding new light on the magnitude and pervasiveness of a critical situation which may pose a serious risk to vulnerable patient populations and, at the same time, may dilute the value of ethical and legitimate SC therapies currently being developed for patients through rigorous preclinical and clinical testing.

The unique ability of stem cells (SCs) to self-renew has prompted basic and clinical investigators to explore their utility for functional restoration of damaged or diseased tissues and organs [1–3]. Results obtained from investigations of different SC types have demonstrated great potential for treating various previously untreatable medical conditions [2, 4, 5]. However, SC research is also often associated with inflated expectations over regenerative capabilities, and the ability to bring working therapies to diseases currently listed as “unmet medical needs” [6, 7]. Although such notions have created significant support for funding legitimate SC research, they have also created strong public demand for the immediate availability of novel SC treatments. This gap between the potential of medical innovation and unmet medical needs has created an opportunity for many dubious “stem cell clinics” to promise availability of SC therapies for various conditions, while providing neither proper scientific support nor validated clinical experiences for these claims. Several publications have attempted to quantify the magnitude of this problem by collecting online information on clinics and businesses in different countries offering unproven stem cell interventions (SCI)
for both cosmetic and medical purposes [8–19]. These thinly disguised for-profit businesses continue to exploit a wide base of vulnerable patients, using unproven therapeutic claims that solicit false hopes of providing new and effective treatments. As unproven SCIs do not have the benefit of payor/insurance coverage, patients are also exploited financially by being charged thousands of dollars to receive these unproven interventions. According to Srivastava et al., unproven cellular therapies are characterized by an unclear scientific rationale, an unknown mechanism of action, insufficient preclinical data regarding their safety profile, unconfirmed product quality, inadequate information disclosure to the patient, untested administration methods, and uncontrolled experimentation in humans [20].

Several guidelines and recommendations have been proposed to limit or eliminate such practices [7, 21–28], and patient advocacy groups and medical societies have been encouraged to work together, in conjunction with regulatory agencies, to raise awareness and educate physicians and patients about the differences between properly tested SC therapies and unproven SCIs [29, 30]. Despite these efforts, unregulated access to unproven SCIs seems to continue to progress, with current regulatory and legal actions unable to control it. In this review, we offer a comprehensive retrospective analysis of adverse events reported for patients receiving unproven SCIs, while capturing factors that contribute to their on-going use.

**STEM CELLS: SEPARATING HOPE FROM HYPE**

The continuing SC plethora and the associated ethical controversies started at the end of the 20th century with the isolation of pluripotent SCs from the inner cell mass of early human embryos by James Thomson (University of Wisconsin, U.S.) and from fetal gonadal cells by John Gearhart (Johns Hopkins University, U.S.) [31, 32]. Soon after, the ability to differentiate pluripotent SCs ex vivo into specialized tissue cells of ectodermal, mesodermal, and endodermal lineages was demonstrated [33]. In 2006, Shinya Yamanaka (Japan) generated induced pluripotent stem cells (iPSCs) from differentiated, mature cells normally incapable of reverting back into true SCs, by up-regulating early acting transcription factors using inserted genes [34]. Nevertheless, the ethical controversies resulting from human embryo sourcing for the generation of embryonic stem cells (ESCs) have hindered the wide spread clinical use of ESC derived products. Likewise, translational challenges and adverse events experienced in clinical trials of iPSC derived cellular products have limited their clinical applications [35–37].

Adult-type SCs are presently a much more feasible and immediate option for clinical applications, with less ethical controversy [38]. Mesenchymal stromal cells (MSCs), which function as multipotent adult SCs, have intrigued the scientific community with their potential therapeutic effects, resulting in many clinical trials but few marketing approvals [39, 40]. Adipose tissue-derived MSCs have become the most popular cell type exploited by many spurious SC clinics because of cell harvesting ease through relatively minor procedures, such as liposuction [9, 41].

Researchers’ over-enthusiasm and media portrayal of scientific achievements in regenerative medicine by applying adult-type SCs has overly inflated the potential of such therapies suggesting wide availability of diverse SC-based treatments in the near future [42]. This coverage fuels public expectations for accelerated access to such treatments and creates opportunities for deceptive trade practices without evidence [43, 44]. To eventually generate a safe and efficacious product, the clinical development path for SC and other somatic cell and gene-based therapeutics is long and financially draining [45]. Therapeutic SC reality, therefore, falls far short of these expectations, and unproven SCI offerings abound unregulated to fill this gap.

**SAFETY INCIDENTS REPORTED AFTER RECEIVING UNPROVEN SCIs**

To evaluate the potential risks of receiving unproven SCIs, literature, and web-based searches were conducted for available adverse event cases reported to date (see Tables 1–2). PubMed and Google search engines were used during January, 2018 to locate cases describing acute or chronic complications as well as death after administration of unproven SCIs into humans. The following terms and keywords were used interchangeably during the PubMed search: “unproven,” “unauthorized,” “Stem cell,” “interventions,” “tourism” and “clinic,” and in addition the following terms were added during the Google search: “complication,” “death,” “neoplasm,” “tumor,” “infection,” and “inflammation.” Searches were limited to English-language literature, with no date limits. Scientific literature and also mass media reports were reviewed by two independent reviewers for inclusion of relevant evidence. Differences in selections were addressed by discussions producing mutual agreements. Additional cases were identified through supplemental materials (e.g., review articles) not identified in the initial search.

The PubMed database search yielded 885 results that were reviewed together with the first five pages of the Google search results. A total of 35 cases describing acute or chronic complications or death following an alleged SCI administration were identified: 19 cases came from the scientific literature, and 16 cases were mass media reports (Tables 1–2). To assess the reliability of the reported cases, reporting criteria for identified cases in the scientific literature were evaluated against the CARE case report guidelines [69]. Reports failing to meet these reporting criteria were categorized as inadequate (n = 9). Although they were meant to be written in the most understandable lay language, some media reports of patients receiving unproven SCIs showed high level of technical details in reporting (n = 5), enabling us to extract all necessary information. This level of responsible reporting is encouraged and considered a powerful tool for educating the public and the scientific community.

The first unproven SCI adverse event from this search dates to 2001: a child (age 13 at the time of admission) suffering from ataxia telangiectasia, for which his parents took him to Russia in 2001, 2002, and 2004 to receive allogeneic fetal neural SC injections into both the cerebellum and the cerebrospinal fluid. In 2005, the child presented to Sheba Medical Center, Israel, complaining of recurrent headaches. An infratentorial brain lesion was identified by MRI, and the patient underwent brain surgery in 2006 to remove the lesion. Neuro-pathological examination of the mass confirmed a glioneural neoplasm originating from donor neural SCs [46]. In further cases examinations, 12 of 35 patients received adipose tissue-derived cells and three patients received xenogeneic SCs, none
| Gender | Age at diagnosis or death | Country where intervention took place | Condition | Alleged type of cellular intervention | Site of injections | Complications | Diagnosis | Reference |
|--------|--------------------------|--------------------------------------|-----------|--------------------------------------|-------------------|--------------|-----------|-----------|
| Male   | 13 years                 | Israel                               | Ataxia telangiectasia | Fetal neural stem cells (SCs) | Direct injection into the cerebellum and the cerebrospinal fluid (CSF) | Neoplastic | Glioneural neoplasms in the brain and the cauda equina originated from the donor neural cells | [46] |
| Female | 46 years                 | Thailand                             | Lupus nephrites | Hematopoietic SCs | Percutaneous injection into the renal regions on both sides (blindly) | Neoplastic | Multiple angiomyloloproliferative renal lesions | [47] |
| Female | 17 years                 | United States                        | Multiple sclerosis | Allogeneic cord blood mesenchymal stromal cells (MSCs) and autologous adipose derived stromal cells | Intrathecal injection and intravenous infusion | Neurological | Severe demyelinating encephalomyelitis | [48] |
| Male   | 66 years                 | United States                        | Ischemic stroke | MSCs, embryonic, and fetal neural SCs | Intrathecal injections | Neoplastic | Glioproliferative lesions in the thoracic spinal cord and thecal sac, originating from exogenous cells | [49] |
| Female | 63 years                 | United States                        | Face lift | Fatty aspirate from the abdominal wall in a procedure called “stem cell face lift” | Facial injection | Infectious | Necrotizing metachronous facial ulcerations | [50] |
| Female | 18 years                 | United States                        | T10-11 fracture dislocation and associated spinal cord injury | Olfactory mucosal cells | Intraspinal transplantation | Neoplastic | Intramedullary spinal mass consisting of olfactory epithelium and large amounts of mucous | [51] |
| Female | 72 years                 | United States                        | Age-related macular degeneration (AMD) | Autologous adipose derived stromal cells | Intravitreal injections | Loss of vision | Vitreous hemorrhage and possible retinal detachment in both eyes. One year after the injection, retinal atrophy and complete loss of vision in both eyes | [52] |
| Female | 78 years                 | United States                        | AMD | Autologous adipose derived stromal cells | Intravitreal injections | Loss of vision | Vitreous hemorrhages, diffuse intraretinal and preretal hemorrhages and retinal detachment in the left eye. One year after injection, perception of hand movement in the right eye and 20/200 vision in the left eye | [52] |

(Continues)
| Gender | Age at diagnosis or death | Country of residence | Condition | Alleged type of cellular intervention | Site of injections | Complications | Diagnosis |
|--------|--------------------------|----------------------|-----------|--------------------------------------|------------------|--------------|-----------|
| Female | 88 years                 | United States        | AMD       | Autologous adipose derived stromal cells | Intravitreal injections | Loss of vision | Retinal detachment with proliferative vitreoretinopathy in the right eye and geographic atrophy with a superotemporal cryopexy scar in the left eye. One year after the injection, visual acuity was perception of hand movement in the right eye and light perception in the left eye. |
| NA     | 19 years                 | NA (Western country) | Spinal cord injury | Olfactory ensheathing fetal cells (OECs) | Spinal injection | Infectious Meningitis, CSF pleocytosis |
| NA     | 22 years                 | NA (Western country) | Spinal cord injury | OECs | Spinal injection | Infectious, gastrointestinal Meningitis, gastrointestinal bleeding, pneumonia. |
| NA     | 22 years                 | NA (Western country) | Spinal cord injury | OECs | Spinal injection | Infectious Meningitis, Stevens-Johnson syndrome |
| NA     | 35 years                 | NA (Western country) | Spinal cord injury | OECs | Spinal injection | Febrile illness Fever, headache |
| NA     | 47 years                 | NA (Western country) | Spinal cord injury | OECs | Spinal injection | Febrile illness Fever |
| Female | 27 years                 | Egypt                | Acute transverse myelitis | MSCs | Intrathecal injection | Autoimmune reaction Acute disseminated encephalomyelitis |
| Male   | 41 years                 | NA                   | Hypertrophic cardiomyopathy | Autologous “precursor” cells | Myocardial injection | Cardiovascular Ventricular fibrillation |
| Male   | 41 years                 | NA                   | Cervical herniated intervertebral disc | Adipose derived MSCs | Intravenous infusion | Cardiovascular Pulmonary embolism |
| NA     | NA                       | Netherlands          | Stem cells (not specified) | NA | Autoimmune reaction (allergic) | NA |
| Female | 71 years                 | Japan                | Chronic kidney failure | Adipose derived MSCs | Intravenous infusion | Neurological NA |
| Gender | Age at diagnosis or death | Country of residence | Country where intervention took place | Condition | Alleged type of cellular intervention | Site of injections | Complications | Diagnosis |
|--------|--------------------------|----------------------|--------------------------------------|-----------|--------------------------------------|-------------------|--------------|-----------|
| Male   | 18 months                | Italy                | Germany (Xcell Center)               | Not specified neurological condition | Bone marrow derived stem cells (SCs) | Direct injection into the brain | Neurological | Internal brain hemorrhage, death |
| Male   | 10 years                 | Azerbaijan           | Germany (Xcell Center)              | Cerebral palsy                       | Bone marrow derived SCs            | Direct injection into the brain | Neurological | Internal brain hemorrhage |
| Female | 69 years                 | United states        | Dominican Republic (For-profit procedure performed by Dr. Zannos Grekos) | Leg numbness and difficulty walking after breast cancer chemotherapy related complications | Grossly filtered bone marrow aspirate | Injection into the right carotid artery | Cerebrovascular | Stroke, death |
| Male   | 77 years                 | United States        | Dominican Republic (For-profit procedure, supervised by Dr. Zannos Grekos) | Pulmonary hypertension               | Adipose derived stromal cells       | Intravenous infusion          | Cardiovascular | Cardiac arrest, death |
| Male   | 73 years                 | South Korea          | Japan (RNL Bio)                     | NA                                    | Adipose derived stromal cells       | NA                            | Cardiovascular | Pulmonary embolism, death |
| Male   | 61 years                 | South Korea          | China (RNL Bio)                     | Diabetes                             | Adipose derived stromal cells       | NA                            | NA           | Death |
| Female | 59 years                 | United states        | United States (Boneogenesis Institute) | Idiopathic bronchiectasis            | Non-specified stem cell intervention | NA                            | NA           | Death |
| Male   | 27 years                 | China                | China (Chinese army’s 455 PLA Hospital) | Disabilities from a minor stroke   | Allogenic SCs (not specified)       | Spinal and intramuscular injections | NA           | Death |
| Female | 63 years                 | China                | China (Beijing Military General Hospital) | Hepatitis B related lifelong liver cirrhosis | NA                                    | NA                            | NA           | Coma, death |
| Female | NA                       | United States        | United States (a clinic in Beverly Hills) | Face lift                          | Adipose derived stromal cells       | Injections around the eye    | NA           | Bone-like growth in the eyelid |
| Male   | 72 years                 | Philippines          | Germany                             | Liver cancer                         | Animal based (xenogeneic) SCs       | NA                            | Infectious   | Pneumonia |
| Male   | 77 years                 | Philippines          | Germany                             | Pneumonia                            | Animal based (xenogeneic) SCs       | NA                            | Infectious   | Pneumonia |
| Male   | NA                       | Philippines          | Germany                             | Heart disease                        | Animal based (xenogeneic) SCs       | NA                            | NA           | NA |
| Female | 75 years                 | Australia            | Australia (Macquarie Stem Cell Clinic in Liverpool) | Dementia                           | Autologous adipose stromal cells    | NA                            | Cardiovascular | Uncontrolled blood loss during the liposuction procedure, hypovolemic shock, and death |
| Female | NA                       | Australia            | Russia (the National Pirogov Medical Surgical Centre) | Neurological disorder, stiff person syndrome | Autologous hematopoietic SCs        | Intravenous infusion          | Cardiovascular | Heart attack, death |
| Male   | 58 years                 | Russia               | Russia                              | Aging                                | Human embryonic SCs                 | Skin injection                | Neoplastic    | Pea sized tumors |

Table 2. Reported cases in mass media which received unproven stem cell interventions
Factors Contributing to the Emergence and Global Rise of Unproven SCI

Based on the cases collected, we identified three domains that may contribute to ongoing use of unproven SCIs with strong relationships between each other: the ethical domain, constituting the main concern, where promises of SC therapies to the public should be truthful and accurate, the scientific domain, where safety and efficacy of the treatment should remain a foremost priority, and the regulatory domain, where a balance should be struck between accelerated SC-based therapeutic development and compiling well-characterized safety and efficacy data to ultimately benefit patients.

The Interface Between Ethics and Rigorous Scientific and Clinical Research

Despite some studies describing MSC risks of promoting tumor growth and certain infections [72], MSCs are considered safe when tested in carefully designed, well-controlled clinical studies and applied in indications suited to their applications [73]. Preclinical testing including in vitro and in vivo assays based on well-designed experiments are essential to ensure sufficient knowledge of the safety and efficacy of a treatment before administration into humans [74]. All new cellular therapy products tested clinically should be produced under Good Manufacturing Practice conditions and tested under Good Clinical Practice to ensure consistent quality of the administered product, the clinical competence of personnel administering the therapy, and the safety and well-being of clinical trial participants [74, 75]. This rigorous code of conduct is meticulously adhered to by all approved, legitimate clinical trials investigating SC-based therapies to ensure adequate evidence synthesis [76, 77]. This process is also subject to thorough quality systems, in which documentation and reporting play a major role [78]. In contrast, SC clinics and companies treating patients in inadequately equipped facilities with nonqualified personnel do not adhere to these criteria. These clinics usually fail to establish requisite safety and efficacy profiles for their SCIs as mandated by regulations, and thus lack the knowledge and accountability for proper dose regimens, SC quality and counts, and optimal route and method of administration [41]. Moreover, objective treatment information for cases of unproven SCIs is generally lacking, relying primarily on patient testimony. This makes traceability challenging and cannot ensure that data and reported results are credible and accurate, and moreover, it cannot guarantee that patient rights, integrity, and confidentiality were protected. This modus operandi places treated patients at great risk, leading to serious adverse events, directly or indirectly related to SCIs. Lack of proper safety reporting also extends to human studies investigating novel therapies [79].

Aside from questionable scientific rigor for using unproven interventions, the dilemmas surrounding these practices challenge the ethical boundaries of honesty and dignity, with direct impact on genuine rights of human autonomy—a primary motive for swift actions and de facto solutions [80]. In most of the reported cases, patients were desperate with noncurable chronic disease where the “right to try” concept to administer experimental treatments operates [44]. This desperation adds complexity to treatment scenarios since clinics offering unproven SCIs also develop strategies to exploit these desperate patients [42, 80]. Not all SC clinics take the same approach, but many websites advertising such interventions repeat a general theme featuring sentimental messaging and patients’ testimonies to benefits and cures. Patients seeking these services have been found to use crowdfunding campaigns with captivating personal narratives and misleading statements about potential benefits and absence of risks to defray the costs of the procedure [81]. The question raised is often: “Is it ethical to administer an unproven intervention that might provide a benefit, but has not been subjected to accepted standards of scientific and clinical research rigor and evidence?” The rise of the “right to try” argument compels heavy refocus on the scientific and ethical bases behind current medical product testing and approval frameworks. Despite possibilities for vast improvements that might be introduced into such frameworks, current regulatory pathways remain the best guarantee for both quality and safety of newly approved products to protect patients from potential harm. Most importantly, physicians who are involved in offering or providing unproven SCIs which lack the appropriate scientific evidence, are violating the trust of their patients and subjecting them to unjustifiable risks [82].

Regulatory Issues Related to the Use of Unproven SCI

Currently, the U.S. has the largest number of SC clinics globally [10]. In 1997, the Food and Drug Administration (FDA) established a regulatory plan for human cells, tissues, and cellular or tissue-based products (HCT/Ps). This was followed by three separate parts and rules in 1998, 1999, and 2000, to be implemented together in Title 21 of the Code of Federal Regulations Part 1271 (21 CFR 1271) in 2001 [83], becoming active in May, 2005.
According to 21 CFR 1271, HCT/Ps are not considered biological products and not regulated by the FDA when they are minimally manipulated, intended for homologous use, or if they are removed and implanted into the same patient in the same surgical procedure. This description has shown to be key to enabling unproven SCIs. Many unproven SC clinics escape FDA regulatory scrutiny by claiming that their therapy falls under these criteria and therefore does not require FDA approval. To clarify this situation, the FDA published two guidances in 2014 [84, 85] stating that the techniques used during the preparation of SC-based therapies isolating the stromal vascular fraction are not considered “minimal manipulation.” The FDA also clarified their criteria for the “same surgical procedure exception,” and that such products are to be regulated as drugs, devices, and/or biological products (21 CFR 1271.20) and subject to Section 351 of the Public Health Service Act and applicable regulations [84]. Since 2011, the FDA has sent several warning letters to many dubious clinics that violate these rules [21] and has held several workshops to promote proper development of SC-based therapies [86]. Most FDA warning letters were for marketing an unproven SCI that falls under FDA authority. These letters also revealed that some companies that do not directly provide SCIs exploit the term “stem cells” in their marketing of devices and cosmetics for enhancing SC functions, or for activating or extracting SCs for re-injection. This pattern of exploiting scientific terms for device marketing, especially for cosmetics has also extended to other advanced therapeutics, such as gene therapies. Recently, the FDA published a warning statement about the “do it yourself” kits for gene therapy production and administration commercialized by a “biohacker” movement [87].

In the European Union (EU), SC-based therapies received official definition by the European Medicines Agency (EMA) in 2001 under Directive 2001/83/EC as “cells or tissues that have been manipulated to change their biological characteristics or cells or tissues not intended to be used for the same essential functions in the body. They can be used to cure, diagnose or prevent diseases” [88]. General aspects of cellular therapy were established in guidelines for human cell-based medicinal products (EMEA/CHMP/410869/2006). The 1394/2007 regulation established rules that regulate the Advanced Therapy Medicinal Products (ATMPs) throughout Europe under EMA authority. From 2008 to 2011, a transition period was allowed for all cellular therapy providers to comply with these new regulations [89]. The company XCell Center (Düsseldorf, Germany) exploited a legal loophole in the German regulations and the new EU regulations during this transitional period to provide bone marrow SC-based interventions. The Center closed in 2010 after the death of an 18-month old child from internal brain hemorrhage [90].

Several regulatory pathways are currently available to facilitate patient access to and benefit from therapeutics still being investigated under rigorous scientific research practices. This “compassionate use of investigational drugs” has a clear regulatory framework in both Europe and the U.S. Through the treating physician, patients in the U.S. who are terminally ill and fail to meet inclusion criteria for clinical trial enrollment can request access to investigational therapeutics. This access can be obtained through two pathways, either the “expanded access programs,” where a drug or biologic in late stage development can be accessed by a wider patient base, or the “single patient expanded access” pathway, where the treating physician requests access to an unlicensed therapeutic from the manufacturer. The manufacturer decides to provide the patient with the experimental drug while simultaneous FDA approval for use is obtained [91]. Moreover, the FDA has implemented the Regenerative Medicine Advanced Therapy designation, offering incentives to developers of novel therapeutics, similar to the “breakthrough designation,” such as accelerated approval, among others [92]. Although these legitimate tools are already available to enable accelerated access to potentially beneficial experimental therapies for severely ill patients, the current proposed federal “right to try” legislation in the U.S. may weaken the agency’s enforcement ability [93].

In the EU, compassionate use allows member states to permit use of unlicensed medicinal products for patients with serious, debilitating, long lasting conditions. Another option is the hospital exemption, where use of ATMPs, including SC-based therapies, is possible for patients on an individualized basis and under the responsibility of the treating physician [94]. Accelerated development pathways for “unmet medical needs” products have also been developed in the U.S. and EU to encourage pharmaceutical companies to invest in such products and to accelerate product availability with shorter development timelines compared to regular therapeutics [94, 95]. Perhaps not coincidentally, “unmet medical needs” are the usual targets for unproven SCI providers. To that end, regulatory agencies are expected to implement a comprehensive policy framework and enforcement measures to clearly delineate SC therapeutic development that require agency oversight and to control the rising tide of direct-to-consumer marketing of unproven SCIs that put increasing numbers of patients at risk [22, 28].

**SUMMARY**

Increasing use of unproven SCIs is a complicated, multifactorial problem that requires the attention of all stakeholders on national and international levels to be properly addressed. Collected evidence indicates substantial patient exploitation using the “power of hope,” and risks using unproven SCIs. Two limitations to this review exist, making it challenging to draw strong correlations between unproven SCIs and reported safety incidents: first, the number of cases identified through a variety of search strategies is considered small and under-represented; second, most of the cases reported from both scientific publications and mass media suffer from incomplete information on the SCI applied. It is expected that the true number of cases receiving unproven SCIs is much larger than the one reported. This situation places more importance on proper adherence to international standards of ethics and science in designing, conducting, recording, and reporting clinical studies of new SC therapies, critical to protecting vulnerable patient populations and providing essential evidence for safety and efficacy determinations. Despite the recent action of the FDA to seek permanent injunctions against two SC clinics advertising unproven SCIs is being hailed as a triumph of law and science-based safeguarding over unethical and potentially dangerous practices [96], the current situation requires relentless and immediate responses to be sufficiently contained.

**AUTHOR CONTRIBUTIONS**

G.B.: conception and design, manuscript writing; M.E.: conception and design, data collection and interpretation,
manuscript writing; M.A.: conception and design, data collection and interpretation, manuscript writing, final approval of manuscript.

**Disclosure of Potential Conflicts of Interest**

The authors indicated no potential conflicts of interest.

**References**

1. Lodi D, Ianniatti T, Palmieri B. Stem cells in clinical practice: Applications and warnings. J Exp Clin Cancer Res 2011;30:9.
2. Watt FM, Driskell RK. The therapeutic potential of stem cells. Philos Trans R Soc B Biol Sci 2010;365:155–163.
3. Lerou PH, Daley GQ. Therapeutic potential of embryonic stem cells. Blood Rev 2005;19:321–331.
4. Daley GQ. The promise and perils of stem cell therapeutics. Cell Stem Cell 2012;10:740–749.
5. Abou-El-Enein M, Bauer G, Reinke P et al. A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. Trends Mol Med 2014;20:632–642.
6. Murdoch CE, Scott CT. Stem cell tourism and the power of hope. Am J Bioeth 2010;10:16–23.
7. Caullfield T, Sipp D, Murry CE et al. Confronting stem cell hype. Science 2016;352:776–777.
8. McMahon DS. The global industry for unproven stem cell interventions and stem cell tourism. Tissue Eng Regen Med 2014;11:1–9.
9. Turner L, Knoepfler P. Selling stem cells in the USA: Assessing the direct-to-consumer industry. Cell Stem Cell 2016;19:154–157.
10. Berger I, Ahmad A, Bansal A et al. Global distribution of businesses marketing stem cell-based interventions. Cell Stem Cell 2016;19:158–162.
11. Taylor-Weiner H, Graff Zivin J. Medicine’s wild west—unlicensed stem-cell clinics in the United States. N Engl J Med 2015;373:985–987.
12. Fung M, Yuan Y, Atkins H et al. Responsible translation of stem cell research: An assessment of clinical trial registration and publications. Stem Cell Reports 2017;8:1190–1201.
13. Caplan A, Levine B. Hope, hype and help: Ethically assessing the growing market in stem cell therapies. Am J Bioeth 2010;10:24–25.
14. Ogbovu U, Rachul C, Caullfield T. Reassessing direct-to-consumer portrayals of unproven stem cell therapies: Is it getting better? Regen Med 2013;8:361–369.
15. Liang BA, Mackey TK. Stem cells, Dot-Com. Sci Transl Med 2012;4:151cm9–151cm9.
16. Ryan KA, Sanders AN, Wang DD et al. Tracking the rise of stem cell tourism. Regen Med 2010;5:27–33.
17. Petersen A, MacGregor C, Munsie M. Stem cell miracles or Russian roulette?: Patients’ use of digital media to campaign for access to clinically unproven treatments. Heal Risk Soc 2016;17:592–604.
18. McLean AK, Stewart C, Kerridge I. Untested, unproven, and unethical: The promotion and provision of autologous stem cell therapies in Australia. Stem Cell Res Ther 2015;6:33.
19. Regenber AC, Hutchinson LA, Schanker B et al. Medicine on the fringe: Stem cell-based interventions in advance of evidence. Stem Cells 2009;27:2312–2319.
20. Srivastava A, Mason C, Wagena E et al. Part I: Defining unproven cellular therapies. Cytotherapy 2016;18:117–119.
21. Sipp D. Direct-to-consumer stem cell marketing and regulatory responses. Stem Cells Translational Medicine 2013;2:638–640.
22. Sipp D, Caullfield T, Kaye J et al. Marketing of unproven cell-based interventions: A call to action. Sci Trans Med 2017;9:eaao0426.
23. Master Z, Resnik DB. Stem-cell tourism and scientific responsibility. Stem-cell researchers are in a unique position to curb the problem of stem-cell tourism. EMBO Rep. 2011;12:992–996.
24. Zarzeczny A, Caullfield T, Ogbovu U et al. Professional regulation: A potentially valuable tool in responding to “stem cell tourism.”. Stem Cell Reports 2014;3:379–384.
25. Ikonomou L, Freishart RJ, Wagner DE et al. The global emergence of unregulated stem cell treatments for respiratory diseases: Professional societies need to act. Ann Am Thorac Soc 2016;13:1205–1207.
26. Gunter KC, Caplan AL, Mason C et al. Cell therapy medical tourism: Time for action. Cytotherapy 2010;12:965–968.
27. Levine AD, Wolf LE. The roles and responsibilities of physicians in patients’ decisions about unproven stem cell therapies. J Law Med Ethics 2012;40:122–134.
28. Knoepfler PS, Turner LG. The FDA and the US direct-to-consumer marketplace for stem cell interventions: A temporal analysis. Regen Med 2018;13:19–27.
29. Weiss DJ, Turner L, Levine AD et al. Medical societies, patient education initiatives, public debate and marketing of unproven stem cell interventions. Cytotherapy 2017;20:165–168.
30. Bauer G, Abou-El-Enein M, Kent A et al. The path to successful commercialization of stem cells. Cytokine Growth Factor Rev 2009;20:186–197.
31. Shamboldt MJ, Axelman J, Wang S et al. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc. Natl. Acad. Sci. USA 1998;95:13726–13731.
32. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145–1147.
33. Reubinoff BE, Pera MF, Fong CY et al. Embryonic stem cell lines from human blastocysts: Somatic differentiation in vitro. Nat Biotechnol 2000;18:399–404.
34. Takashiki K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663–676.
35. Lo B, Parham L. Ethical issues in stem cell research. Endocr Rev 2009;30:204–213.
36. Robertson JA. Human embryonic stem cell research: Ethical and legal issues. Nat Rev Genet 2001;2:74–78.
37. Saha K, Jaensch R. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 2009;5:584–595.
38. Dulak J, Szade K, Szade A et al. Adult stem cells: Hopes and hypoves of regenerative medicine. Acta Biochim Pol 2015;62:329–337.
39. Keating A. Mesenchymal stromal cells. Curr Opin Hematol 2006;13:419–425.
40. Da Silva Meirelles L, Fontes AM, Covas DT et al. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. CytoKine Growth Factor Rev 2009;20:419–427.
41. Turner L. US stem cell clinics, patient safety, and the FDA. Trends Mol Med 2015;21:271–273.
42. Kamenova K, Caullfield T. Stem cell hype: Media portrayal of therapy translation. Sci Transl Med 2015;7:278ps4–278ps4.
43. Petersen A, Seear K, Munsie M. Therapeutic journeys: The hopeful travails of stem cell tourists. Sociol Health Illn 2014;36:670–685.
44. Matthews KRW, Ilitis AS. Unproven stem cell-based interventions and achieving a compromise policy among the multiple stakeholders. BMC Med Ethics 2015;16:75.
45. Abou-El-Enein M, Elsharnouby A, Reinke P. Overcoming challenges facing advanced therapies in the EU market. Cell Stem Cell 2016;19:293–297.
46. Amarioglio N, Hirshberg A, Scheithauer BW et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009;6:e2021–e2031.
47. Thirabanjasak D, Tantwongse K, Thorner PS. Angiomyeloproliferative lesions following autologous stem cell therapy. J Am Soc Nephrol 2010;21:1218–1222.
48. Alderazi YJ, Coons SW, Chapman K. Catastrophic demyelinating encephalomyelitis after intrathecal and intravenous stem cell transplantation in a patient with multiple sclerosis. J Child Neurol 2012;27:632–635.
49. Berkowitz AL, Miller MB, Mir SA et al. Glioproliferative lesion of the spinal cord as a complication of “stem-cell tourism”. N Engl J Med 2016;375:196–198.
50. Dokie M, Bailey J, Bhavsar D et al. Necrotizing metachronous facial ulceration after “stem cell face lift”. Ann Plast Surg 2013;70:392–396.
51. Dlouhy BJ, Awe O, Rao RC et al. Autograft-derived spinal cord mass...
following olfactory mucosal cell transplantation in a spinal cord injury patient. J Neurosurg Spine 2014;21:618–622.
52. Kuriyan AE, Albini TA, Townsend JH et al. Vision loss after intravitreal injection of autologous “Stem Cells” for AMD. N Engl J Med 2017;376:1047–1053.
53. Dobkin BH, Curt A, Guest J. Cellular transplants in China: Observational study from the largest human experiment in chronic spinal cord injury. Neurorehabil Neural Repair 2006;20:5–11.
54. Bellizio M, Celli H. Commentary on “possible induction of acute disseminated encephalomyelitis (ADEM)-like demyelinating illness by intrathecal mesenchymal stem cell injection”. J Clin Neurosci 2013;20:312–313.
55. Pytel P, Husain A, Moskovitz I et al. Ventricular fibrillation following autologous intramyocardial cell therapy for inherited cardiomyopathy. Cardiovasc Pathol 2010;19:e33–e36.
56. Jung JW, Kwon M, Choi JC et al. Familial occurrence of pulmonary emphysema, for intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J 2013;54:1293–1296.
57. Sheldon T. Dutch clinic is ordered to stop giving stem cell therapy. BMJ 2006;333:770.
58. Ikka T, Fujita M, Yashiro Y et al. Letter recent court ruling in Japan exemplifies another layer. Stem 2015;17:507–508.
59. The Telegraph. 2011. Europe’s Largest Stem Cell Clinic Shut Down After Death Of Baby [Internet]. Available at https://www.telegraph.co.uk/news/worldnews/europe/greece/8500223/Europes-largest-stem-cell-clinic-shut-down-after-death-of-baby.html. [Accessed 27th November 2017]
60. Naples Daily News. 2014. Bonita Springs Stem Cell Doctor Grekos Loses Two More Rounds In Court [Internet]. Available at http://archive.naplesnews.com/news/local/bonita-springs-stem-cell-doctor-grekos-loses-two-more-rounds-in-court-ep-589350147-337085341.html. [Accessed 27th November 2017]
61. CNN International Edition. 2010. South Korean Company Cleared in Deaths Following Stem Cell Therapy [Internet]. Available at http://edition.cnn.com/2010/WORLD/asiapcf/12/14/south-korea.stem-cell/index.html. [Accessed 27th November 2017]
62. Turner L. Medical Malpractice Lawsuit Following Death of Stem Cell Recipient [Internet]. 2012. Available at http://www.healthintheglobalvillage.com/medical -malpractice-lawsuit-following-death-of -stem-cell-recipient/. [Accessed 27th November 2017]
63. Reuters China “stem cell therapies” offer heartbreak for many [Internet]. 2011. Available at https://www.reuters.com/article/us-stemcell-scams/china-stem-cell-therapies-offer-heartbreak-for-many-idUSTRE78K18120110929. [Accessed 27th November 2017]
64. Scientific American. 2012. In the Flesh: The Embedded Dangers of Untested Stem Cells [Internet]. Available at https://www.scientificamerican.com/article/stem-cell -cosmetics/. [Accessed 27th November 2017]
65. Inquirer.net. 2013. Doctors Probe Deaths of 3 Politicians After Stem Cell Treatment. Available at http://lifestyle.inquirer.net/110057/doctors-probe-deaths-of-3-politicians-after-stem-cell-treatment/. [Accessed 27th November 2017]
66. Coroners Court New South Wales. 2016. Report into the Death of Sheila Drysdale [Internet]. Available at http://www.coroners.justice.nsw.gov.au/Documents/FindingsDrysdale.pdf. [Accessed 27th November 2017]
67. Brisbane Times. 2014. Brisbane Mum Dies Undergoing Stem Cell Therapy in Russia [Internet]. Available at https://www.brisbanetimes.com.au/national/qld/qldpolitics/brisbane-mum-dies-undergoing-stem-cell-therapy-in-russia-20140727-zx9uz.html. [Accessed 27th November 2017]
68. Newswise. 2004. Stem Cell Rip-Off [Internet]. Available at http://www.newswise.com/stem-cell-rip-124481. [Accessed 27th November 2017]
69. Gagnier JJ, Kienle G, Altman DG et al. The CARE guidelines: Consensus-based clinical case reporting guideline development. J Med Case Rep 2013;7:223.
70. Kish K, Bookin T, Gabr H. Possible induction of acute disseminated encephalomyelitis (ADEM)-like demyelinating illness by intrathecal mesenchymal stem cell injection. J Clin Neurosci 2013;20:310–312.
71. Horner C, Tenenbaum E, Sipp D et al. Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions.npj Regen Med 2018;3:5.
72. Arango-Rodriguez ML. Could cancer and infection be adverse effects of mesenchymal stromal cell therapy? World J Stem Cells 2015;7:408.
73. Yim H, Jeong H, Cho Y et al. Safety of mesenchymal stem cell therapy: A systematic review and meta-analysis. Cytotherapy 2016;18:5132.
74. Abou-El-Enein M, Duda GN, Gruskia E et al. Strategies for derisking translational processes for biomedical technologies. Trends Biotechnol 2017;35:100–108.
75. Abou-El-Enein M, Römhild K,aiser D et al. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: A novel tailored model for optimizing performance and estimating costs. Cytotherapy 2013;15:362–383.
76. Marks PW, Witten CM, Califf RM. Clarifying stem-cell therapy’s benefits and risks. N Engl J Med 2017;376:1007–1009.
77. Abou-El-Enein M, Grainger DW, Kili S. Registry contributions to strengthening cell and gene therapeutic evidence. Mol Ther 2018;26:1172–1176.
78. Fortunato A, Grainger DW, Abou-El-Enein M. Enhancing patient-level clinical data access to promote evidence-based medicine. Adv Drug Deliv Rev 2018; doi:10.1016/j.addr.2018.01.017. [Epub ahead of print]
79. Toyserkani NM, Jørgensen MG, Abou-El-Enein M. Enhancing patient-level clinical data access to promote evidence-based medicine. Adv Drug Deliv Rev 2018; doi:10.1016/j.addr.2018.01.017. [Epub ahead of print]
80. Marcon AR, Murdoch B, Caufield T. Fake news portrayals of stem cells and stem cell-based products. Adv Drug Deliv Rev 2018;139:264–270.
81. Snyder J, Turner L, Crooks V A. Crowdfunding for unproven stem cell-based interventions. JAMA 2018;319:1935.
82. Ogbugu O, Du J, Kouko Y. The involve- ment of Canadian physicians in promoting and providing unproven and unapproved stem cell treatments. BMC Med Ethics 2018;19:32.
83. United States Food and Drug Adminis tration. 2017. United States Food and Drug Administration. 2017. CFR - Code of Federal Regulations Title 21 part 1271 - Human Cells, Tissues and Cellular and Tissue-Based Products. Available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfr/cfrsearch. cfm?CFRPart=1271. [Accessed 26th March 2018]
84. United States Food and Drug Adminis tration. 2014. Same Surgical Procedure Excep tion under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Excep tion. Available at https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM 4310926.pdf. [Accessed 26th March 2018]
85. United States Food and Drug Adminis tration. 2014. Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products. Available at https://www.fda.gov/assets/docs/FDA%20Draft%20Guidance%20Minimally%20Manipulated%202014.pdf. [Accessed 26th March 2018]
86. United States Food and Drug Adminis tration. 2016. Public Workshop: Scientific Evi- dence in Development of HCT/Ps Subject to Premarket Approval. Available at https:// www.fda.gov/BiologicsBloodVaccines/Newsvacines/events/WorkshopsMeetingsConferences/ucm 492499.htm. [Accessed 26th March 2018]
87. United States Food and Drug Adminis tration. 2017. Information About Self- Administration of Gene Therapy. Available at https://www.fda.gov/BiologicsBloodVaccines/ CellularGeneTherapyProducts/ucm586343.htm. [Accessed 26th March 2018]
88. Official J Eur Union. 2000. Directive 2001/83/EC. Available at https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_ _2012_en.pdf. L 269: 1–15. [Accessed 26th March 2018]
89. Official J Eur Union. 2007. Regulation (EC) No 1344/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 725/2004. Available at https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2007_1344/reg_2007_1344_en.pdf. [Accessed 26th March 2018]
90. Petersen A, Munsie M, Tanner C et al. Stem Cell Tourism and the Political Economy of Hope. London, UK: Palgrave Macmillan, 2017.
91. United States Food and Drug Adminis tration. 2016. Expanded Access to Investiga tional Drugs for Treatment Use — Questions and Answers. Available at https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM351261.pdf. [Accessed 26th March 2018]
92. Marks P, Gottlieb S. Balancing safety and innovation for cell-based regenerative medicine. N Engl J Med 2018;378:954–959.
Bateman-House A, Robertson CT. The federal right to try act of 2017—A wrong turn for access to investigational drugs and the path forward. JAMA Intern Med 2018;178:321.

Elsanhoury A, Sanzenbacher R, Reinke P et al. Accelerating patients’ access to advanced therapies in the EU. Mol Ther Methods Clin Dev 2017;7:15–19.

Knoepfler PS. From bench to FDA to bedside: US regulatory trends for new stem cell therapies. Adv Drug Deliv Rev 2015;82–83:192–196.

United States Food and Drug Administration. 2018. FDA Seeks Permanent Injunctions Against Two Stem Cell Clinics. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607257.htm. [Accessed 14th May 2018]